UK stem-cell specialist ReNeuron and USA-based Millipore Corp have announced the market launch of the former's ReNcell neural stem cell lines for use in non-therapeutic applications.
The firms explained that the launch follows the establishment of a manufacturing and distribution agreement between ReNeuron, now part of Chemicon International, and Millipore that was signed earlier this year. Under the terms of this deal, the US firm will undertake manufacture and supply of the UK group's ReNcell CX and ReNCell VM cell lines and growth media, and will make royalty payments based on sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze